US Patent

US10806743 — Method of administering lactitol to reduce plasma concentration of lactitol

Method of Use · Assigned to Sebela Bt Holdings Inc · Expires 2037-05-12 · 11y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of administering lactitol formulations to treat chronic idiopathic constipation by taking them after or during a meal.

USPTO Abstract

Disclosed herein are formulations comprising lactitol for the treatment of chronic idiopathic constipation. As disclosed herein, the formulations are administered after or during a meal to improve the pharmacokinetics of the formulation. In particular, administration of the formulation after or during a meal decreases the absorption of lactitol and reduces the AUC.

Drugs covered by this patent

Pizensy (LACTITOL) · Braintree Labs

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1516`	—	Pizensy

Patent Metadata

Patent number: US10806743
Jurisdiction: US
Classification: Method of Use
Expires: 2037-05-12
Drug substance claim: No
Drug product claim: No
Assignee: Sebela Bt Holdings Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.